| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442702 | European Journal of Cancer | 2015 | 10 Pages |
Abstract
The unexpectedly low incidence of Her2 overexpression precluded the detection of a significant difference in efficacy on addition of trastuzumab to platinum-based chemotherapy with gemcitabine. However, the satisfactory tolerance of the combination warrants further studies, especially of the cisplatin-based combination, in well-defined patient subsets.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Stéphane Oudard, Stéphane Culine, Yann Vano, François Goldwasser, Christine Théodore, Thierry Nguyen, Eric Voog, Eugeniu Banu, Annick Vieillefond, Franck Priou, Gaël Deplanque, Gwenaëlle Gravis, Alain Ravaud, Jean Michel Vannetzel,